



# Arbutus Biopharma Corporation and Roivant Sciences Ltd. form Genevant Sciences

**Date closed:** 4/12/2018

**Value:** See below

On April 12, 2018, Arbutus Biopharma Corporation (Arbutus), an industry-leading hepatitis B virus (HBV) therapeutic solutions company and Roivant Sciences Ltd. (Roivant) announced that they have entered into an agreement to launch Genevant Sciences (Genevant), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute \$37.5 million in transaction-related seed capital for Genevant.

BLG acted as Canadian counsel to Arbutus with a team led by [Warren Learmonth](#), that [Stephen Robertson](#) (Corporate), [Randy Morphy](#) (Tax) and [Steve Winder](#) (Employment).

## **For more information, please contact:**

### **Tamara Costa**

National Director, Marketing and Communications

Borden Ladner Gervais LLP

[TCosta@blg.com](mailto:TCosta@blg.com)

416.350.2642



---

## **BLG | Canada's Law Firm**

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[\*\*blg.com\*\*](https://www.blg.com)

© 2022 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.